Most Read Articles
Roshini Claire Anthony, 5 days ago

Individuals with moderate-to-severe plaque psoriasis may reap better long-term improvements in the severity of their condition when treated with guselkumab over secukinumab, according to findings of the phase III ECLIPSE* trial presented at the recent Inflammatory Skin Disease Summit (ISDS 2018) held in Vienna, Austria.

Jairia Dela Cruz, 11 Jan 2019
Use of standard-dose aspirin or other nonsteroidal anti-inflammatory drugs (NSAIDs) appears to confer protection against the risk of endometrial cancer in overweight and obese women, according to a meta-analysis.
4 days ago
Discontinuing the use of tyrosine kinase inhibitors (TKIs) in the treatment of patients with chronic myeloid leukaemia appears to be feasible in real-life clinical practice in the context of close molecular monitoring, a study reports.
5 days ago
There appears to be no clear link between pornography use, even at problematic levels, and erectile dysfunction, a recent US study has shown.

Hydroxychloroquine may protect against cutaneous neonatal lupus

Jairia Dela Cruz
06 Nov 2018

In utero exposure to hydroxychloroquine (HCQ) appears to reduce the risk of developing cutaneous neonatal lupus (cNL) erythematosus, as shown in a multicentre case-control study. Moreover, there is a trend toward delayed rash onset in HCQ-exposed infants with cNL.

These findings may have important clinical relevance as preventing cNL can reduce the occurrence of permanent scarring, such as telangiectasia, epidermal atrophy and cutaneous pigmentation changes, according to the authors.

The study included 122 cNL patients and 434 controls born to women with systemic autoimmune rheumatic diseases (SARDs). Significantly more infants in the control group were exposed to HCQ (34 percent vs 16 percent) or nonfluorinated steroids (44 percent vs 25 percent; p<0.01) in utero.

In multivariate generalized estimating equations (GEE) models, cNL was associated with a lower likelihood of in utero exposure to HCQ (odds ratio [OR], 0.4; 95 percent CI, 0.2–0.7; p<0.01), suggesting that HCQ might protect against cNL. [Ann Rheum Dis 2018;doi:10.1136/annrheumdis-2018-213718]

Factors associated with increased cNL risk included female sex (OR, 1.7; 1.1–2.6; p=0.02) and exposure to maternal anti-La antibody (OR, 2.7; 1.7–4.3; p<0.01).

“Exposure to HCQ remained significantly associated with a reduced cNL risk in the analyses limited to mothers with systemic lupus erythematosus (SLE) and those who developed rash ≤1 month,” the authors said.

Finally, in a secondary analysis including 262 infants with cNL irrespective of maternal diagnosis, HCQ-exposed infants were older at cNL onset compared with nonexposed infants (6.0 vs 4.4 weeks), although the difference was not statistically significant (p=0.21).

The findings regarding HCQ's effect on timing of cNL, despite being inconclusive, are valuable as the survival curves showed a delayed onset of rashes during the first 6 weeks of life in infants exposed to HCQ in utero, the authors pointed out.

A drug frequently used in women with SARDs, HCQ exerts a protective effect through inhibition of toll-like receptor activation and signalling. The drug has been shown to effectively treat subacute cutaneous lupus, which closely resembles cNL. [Arch Dermatol 2012;148:479-484]

“Our study is the first to address the effect of HCQ exposure on cNL. Cutaneous involvement in NL may result in unnecessary medical consultations, investigations and treatments and lead to permanent scarring,” the authors said. “Using an inexpensive and safe medication to prevent cNL and therefore minimize these issues is definitely appealing.”

“All analyses performed suggest that prenatal exposure to HCQ may have an impact on the development of cNL and support the need for further studies addressing the underlying pathophysiology of cNL and potential preventive use of maternal HCQ for cNL,” they added.

The authors acknowledged several limitations to the study. First, medication adherence in mothers was not measured specifically during pregnancy but was determined only during routine prenatal rheumatology follow-up. Second, confounding by indication could have occurred as women with SLE are more likely to be prescribed HCQ than women with other SARDs.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Roshini Claire Anthony, 5 days ago

Individuals with moderate-to-severe plaque psoriasis may reap better long-term improvements in the severity of their condition when treated with guselkumab over secukinumab, according to findings of the phase III ECLIPSE* trial presented at the recent Inflammatory Skin Disease Summit (ISDS 2018) held in Vienna, Austria.

Jairia Dela Cruz, 11 Jan 2019
Use of standard-dose aspirin or other nonsteroidal anti-inflammatory drugs (NSAIDs) appears to confer protection against the risk of endometrial cancer in overweight and obese women, according to a meta-analysis.
4 days ago
Discontinuing the use of tyrosine kinase inhibitors (TKIs) in the treatment of patients with chronic myeloid leukaemia appears to be feasible in real-life clinical practice in the context of close molecular monitoring, a study reports.
5 days ago
There appears to be no clear link between pornography use, even at problematic levels, and erectile dysfunction, a recent US study has shown.